Bicara Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Bicara Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-13.7%
Buyback Yield
| Total Shareholder Yield | -13.7% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Phase III Progress In Head And Neck Cancer Will Reshape Long Term Outlook
Catalysts About Bicara Therapeutics Bicara Therapeutics is a clinical stage biotech company developing bifunctional antibodies for targeted tumor modulation, with a focus on its lead asset FICERA in HPV negative head and neck cancer. What are the underlying business or industry changes driving this perspective?
Pivotal Head And Neck Cancer Trial Will Reshape Prospects For This Bifunctional Antibody Developer
Catalysts About Bicara Therapeutics Bicara Therapeutics is a clinical stage biotech company focused on bifunctional antibodies for targeted tumor modulation, led by its FICERA program in HPV negative head and neck cancer. What are the underlying business or industry changes driving this perspective?Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement
Summary Bicara Therapeutics Inc. maintains a Buy rating, driven by progress in its pivotal phase 3 FORTIFI-HN01 study for 1st-line R/M HPV-negative HNSCC. BCAX's ficerafusp alfa plus KEYTRUDA achieved a 12-month OS of 61% and a confirmed ORR of 54% in phase 1/1b, supporting continued development. Key upcoming catalysts for BCAX include phase 3 interim data in mid-2027 and long-term phase 1b follow-up at ASCO 2026, with near-full enrollment expected by year-end. BCAX is well-capitalized, with more than $414.8M in cash and funding runway into H1 2029, but faces competitive risk from Genmab’s petosemtamab and trial readouts. Read the full article on Seeking AlphaWe're Not Very Worried About Bicara Therapeutics' (NASDAQ:BCAX) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Bicara: Innovative Precision Tumor Targeting
Summary Bicara Therapeutics' lead candidate, ficerafusp alfa, targets EGFR and TGF-beta in tumors, showing promise in hard-to-treat cancers like Head and Neck Squamous Cell Carcinoma. Bicara's financial health is robust, with $489.7 million in cash, ensuring operations through mid-2029, bolstered by a successful IPO and Series C funding. Early clinical data for ficerafusp alfa plus pembrolizumab in HPV-negative HNSCC shows significant antitumor activity and manageable safety, supporting its potential market impact. Bicara's pivotal Phase 2/3 trial could establish ficerafusp alfa as a new standard of care, with a potential market revenue of $1.3 billion annually. Read the full article on Seeking AlphaWe Think Bicara Therapeutics (NASDAQ:BCAX) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me
Summary Bicara Therapeutics is a new biotech firm focusing on innovative cancer treatments, currently advancing its lead candidate, ficerafusp alfa, targeting challenging cancers like HNSCC. BCAX's financial health is strong, with sufficient capital to fund operations for about four years, but relies heavily on the success of ficerafusp alfa. Early trial results for ficerafusp alfa show promise, particularly in HPV-negative HNSCC, but the lack of diverse pipeline and early-stage data pose significant risks. Given the long wait for potential approval and high volatility, BCAX is a speculative investment better suited for patient, risk-tolerant investors, and I would personally watch for a favorable entry point. Read the full article on Seeking AlphaStability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if BCAX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BCAX's dividend payments have been increasing.
Dividend Yield vs Market
| Bicara Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (BCAX) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.4% |
| Analyst forecast (BCAX) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate BCAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BCAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate BCAX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BCAX has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/31 19:54 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bicara Therapeutics Inc. is covered by 16 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Suranjit Mukherjee | BTIG |
| Eric Schmidt | Cantor Fitzgerald & Co. |